Tuesday, 10 November

7:00-8:30 ISPOR RARE DISEASE SPECIAL INTEREST GROUP MEETING (Open to all Attendees) Amber 3-4 (L2)
7:30-8:30 UPDATE ISPOR VISION 2020 Brown 1-2 (L2)
7:30-8:30 EDUCATIONAL SYMPOSIUM Brown 3 (L2)
New Approaches to Capturing Value in Oncology
8:45-11:45 RESEARCH POSTERS - III South Hall (L0)
8:45-9:45 WORKSHOPS - II
W7: Market Access 2020: What Are the Next Challenges? Gold (L2)
W8: Evidence Synthesis Based on Aggregate and Individual-Level Data: Considerations for Use in HTA Decision Making Brown 3 (L2)
W9: Development of Evidence Packages for Regulatory and Reimbursement Submissions in Rare Diseases: Real-World Examples Space 1 (L0)
W10: Moving the Science Forward: Tackling Key Psychometric and Methodological Issues Facing the Field of Clinical Outcome Assessment Space 2 (L0)
W11: Translating Pharmacometrics to Pharmacoeconomics Space 3 (L0)
W12: Optimizing Patient Involvement in Payer Health Care Decisions to Access New Therapies Brown 1-2 (L2)
9:45-10:15 BREAK, EXHIBITS & RESEARCH POSTERS - III South Hall (L0)
10:15-12:00 WELCOME & SECOND PLENARY SESSION Gold (L2)
Outcomes Research: Are We Ready to Put Theory into Practice?
12:00-13:45 LUNCH, EXHIBITS & RESEARCH POSTERS - III South Hall (L0)
12:15-13:30 ISPOR ONCOLOGY SPECIAL INTEREST GROUP MEETING (Open to all Attendees) Space 3 (L0)
12:30-13:30 EDUCATIONAL SYMPOSIUM Gold (L2)
Rare Diseases: Navigating the Road to Approval and Access
12:45-13:45 POSTER AUTHOR DISCUSSION HOUR - III South Hall (L0)
13:45-14:45 ISSUE PANELS - II
IP6: Assessment of the Value of Medical Devices: Can We Simply Apply Processes Established for Drugs or Do We Need to Pursue Separate Processes for Devices? Brown 1-2 (L2)
IP7: Are Current ICER Thresholds Outdated? Does MCDA Offer a More Holistic Approach to Assessing the Value of Innovative Technologies? Space 1 (L0)
IP8: The Cost of No Europe: Are There Costs and Consequences of Localized or Centralized Assessment of Relative Efficacy? Gold (L2)
IP9: Is a Single Evidence Base Possible across Europe? How Should Evidence Generation Efforts Be Focused to Meet Payer Requirements for Market Access? Space 2 (L0)
IP10: Quality-Adjusted Life Years (QUALEY) – Help or Hindrance in Supporting Health Care Decision Making? Brown 3 (L2)
14:45-15:15 BREAK & EXHIBITS South Hall (L0)
15:15-19:15 RESEARCH POSTERS - IV South Hall (L0)
15:15-16:15 ISSUE PANELS - III
IP11: Building Light HTA Approach in Central and Eastern European Countries Based on HTA Recommendations in Western European Countries: More Harm Than Good! Gold (L2)
IP12: What Are the Opportunities and Challenges in Developing Transparency of Clinical (Trial) Data? Brown 1-2 (L2)
IP13: Best Available Evidence for Health Technology Assessment Decision Making: Efficacy or Effectiveness? Space 1 (L0)
IP14: Valuing Health: Have We Really Got It Right? Space 2 (L0)
IP15: The Truth, The Whole Truth, and Nothing but the Truth: Should We Stick to Pragmatic Incrementalism or is It Time to Take Cost-Effectiveness Analyses up to the Level of Disease Modelling? Brown 3 (L2)
16:30-17:30 WORKSHOPS - III
W13: The Role of Value of Information in HTA: Are We Missing an Opportunity? Brown 3 (L2)
W14: Orphan Drug Evidence Requirements for Positive HTA Recommendations Gold (L2)
W15: Sample Size Estimation and Power Calculation for Prospective Observational Studies Space 2 (L0)
W16: Retrospective Health Outcomes Research and Health-Economic Evaluation Based on Real-World Data Analyses in Europe: Data Availability, Strengths and Limitations, and Database-Specific Considerations Space 3 (L0)
W17: Challenges and Solutions to Successfully Determine Real-World Cost-Effectiveness Space 1 (L0)
W18: Utilities in HTA: Challenges for Theory and Practice Now and in the Future Brown 1-2 (L2)
17:30-18:15 EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTERS – IV South Hall (L0)
17:45-18:45 ISPOR FORUMS - II
F7: Conjoint Analysis: Good Research Practices for Statistical Analysis Brown 3 (L2)
F9: Multi-Criteria Decision Making in the Central & Eastern European (CEE) Region: Are We There Yet? Space 2 (L0)

Wednesday, 11 November

7:30-8:30 ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP MEETING (Open to all Attendees) Amber 7 (L2)
7:30-8:30 EDUCATIONAL SYMPOSIUM Brown 3 (L2)
Enriched Real-World Data (IRD): Tapping into the Growing Use of Patient Level Data to Optimize Observational Study Design and Execution
8:45-13:45 RESEARCH POSTERS - V South Hall (L0)
8:45-9:45 WORKSHOPS - IV
W19: Estimation and Prediction of Relative Effectiveness Using Real-World Evidence: Case Studies Brown 1 (L2)
W20: How to Bring PRO Data into Payer Decision Making: PRO Strategies in Pharmaceutical Development Brown 3 (L2)
W21: Optimising the Construction of Indirect Treatment Comparisons to Reflect Country-Specific HTA Requirements Space 1 (L0)
W22: Harnessing “Big Data” and Taming High Dimensional Decision Problems for Economic Evaluation Space 2 (L0)
W23: Adding Value to EQ-5D-3L Valuation Studies: Taking Stock / Reviewing Options Brown 2 (L2)
9:45-10:00 BREAK, EXHIBITS & RESEARCH POSTERS - V South Hall (L0)
10:00-11:00 ISSUE PANELS - IV
IP16: Outcome-Based Agreements: Highly Useful But Too Difficult to Implement – Is That True? Brown 1 (L2)
IP17: Joint Assessments in Europe: Can We Do It and How? Brown 3 (L2)
IP18: To Seek or Not to Seek Parallel European Medicines Agency (EMA)/Health Technology Assessment (HTA) Scientific Advice? Is that the Question Space 1 (L0)
IP19: How Do We Evaluate Technologies Which Are Not Cost-Effective at a Zero Price? Space 2 (L0)
IP20: Patient-Reported Outcomes: Can Their Use in Observational (“Real-World”) Research Be Considered Intervenional? Brown 2 (L2)
11:15-12:30 WELCOME & THIRD PLENARY SESSION Gold (L2)
Recommendations from the ISPOR Multi-Criteria Decision Analysis Emerging Good Practice Task Force and Remaining Controversies
12:30-12:45 ISPOR 18TH ANNUAL EUROPEAN CONGRESS RESEARCH PRESENTATION AWARDS Gold (L2)
12:45-13:45 LUNCH, EXHIBITS & RESEARCH POSTERS - V South Hall (L0)
12:45-13:45 POSTER AUTHOR DISCUSSION HOUR - V South Hall (L0)
12:45-14:45 WORKSHOPS - V
W24: Are Antimicrobials Paving the Way for All Pharmaceuticals? – A Workshop on the Commercial Sustainability of R&D Brown 3 (L2)
W25: Incorporating Equity into Health Technology Assessment: An Illustration and Critical Review of Good Practice Space 1 (L0)
W26: Maximizing Value: Realizing the Potential of Routinely Collected Data Space 2 (L0)
W28: Secondary Analysis of Qualitative Data to Inform the Development of PRO Instruments Brown 1-2 (L2)
14:45-15:00 BREAK South Hall (L0)
15:00-16:00 WORKSHOPS - VI
W29: How Should We Be Responding to Conditional Approvals from HTA Bodies? Brown 3 (L2)
W30: Managing the Effects of Channeling in Relative Effectiveness Studies of Newly Launched Medications Space 1 (L0)
W31: Network Meta Analysis Models for Dose-Response and Class Effects in Decision Making Brown 3 (L2)
W32: How to Combine Open Access Articles and Open Access Economic Evaluation Models in Medications Space 2 (L0)
W33: Uncertainty of Uncertainty Estimates in Economic Modelling of Oncology Brown 1 (L2)
ISPOR Registration Help Desk
Saturday, 7 November
8:00-18:00
Sunday, 8 November
7:00-18:00
Monday, 9 November
7:00-18:00
Tuesday, 10 November
7:00-18:00
Wednesday, 11 November
7:00-16:00